Skip to main content
Guerbet logo

Guerbet — Investor Relations & Filings

Ticker · GBT ISIN · FR0000032526 LEI · 969500WV1U1WQ059L135 PA Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2013-02-18 Regulatory Filings
Country FR France
Listing PA GBT

About Guerbet

https://www.guerbet.com

Guerbet is a global specialist in medical imaging, offering a comprehensive range of solutions and services for diagnostic and interventional procedures. The company develops and manufactures contrast media, medical devices such as injectors, and related software for X-ray, Magnetic Resonance Imaging (MRI), and Interventional Imaging. With a history of innovation dating back to 1926, Guerbet focuses on providing healthcare professionals with tools to enhance diagnostic accuracy and improve patient care. Its portfolio is designed to support a wide array of clinical applications, from initial diagnosis to treatment monitoring.

Recent filings

Filing Released Lang Actions
Guerbet - Le Medical Imaging Drugs Advisory Committee de la FDA recommande l’autorisation de Dotarem®
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a specific event: the FDA's Medical Imaging Drugs Advisory Committee recommending the approval of the drug Dotarem®. This is a corporate announcement regarding regulatory progress and clinical data, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is a press release detailing a significant corporate event (regulatory decision), it fits best under the general category for regulatory announcements or news releases that don't fit a more specific financial or operational category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing regulatory news, although 'LTR' (Legal Proceedings Report) is sometimes used for FDA/regulatory actions, RNS is broader for general news releases. However, since this is a specific announcement about a product approval process, and not a general regulatory filing, I will check other options. It is not an Earnings Release (ER), nor a Management Discussion (MDA). It is a specific announcement of a regulatory event. Given the available codes, RNS (Regulatory Filings - general regulatory announcements and fallback) is the best fit for a press release detailing FDA committee actions, as it is not a core financial report or a specific management/governance document. The length (7074 chars) is substantial, ruling out a simple RPA.
2013-02-18 French
Guerbet - Medical Imaging Drugs Advisory Committee Recommends Approval of Guerbet NDA for Dotarem®
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces the outcome of an advisory committee vote regarding a New Drug Application (NDA) for a product called Dotarem®. This type of announcement, detailing the progress or outcome of regulatory submissions (like FDA review processes) and providing key business updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement about a regulatory event (FDA advisory committee recommendation) rather than a comprehensive financial report (10-K, IR) or a general regulatory filing fallback (RNS), and it focuses on key business/product news, it aligns best with the 'Earnings Release' category, which often includes significant operational or regulatory milestones alongside financial highlights, or sometimes serves as a proxy for major business news announcements when a dedicated 'Regulatory Milestone' code is unavailable. Given the options, 'ER' is the closest fit for a press release announcing a major regulatory development impacting the business, although 'RNS' is also plausible as a general regulatory announcement. However, press releases announcing key operational/regulatory milestones are frequently categorized as ERs in financial databases when they are not full financial reports. I will select ER as it is a major business update announcement.
2013-02-18 English
Guerbet - Chiffre d'affaires 2012
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUE DE PRESSE" and explicitly states "Chiffre d'affaires 2012" (2012 Revenue). It presents consolidated revenue figures broken down by quarter and geography for the full year 2012 compared to 2011. This content is characteristic of an initial announcement of periodic financial results, focusing on key top-line figures (revenue). It is not the comprehensive Annual Report (10-K) or the detailed Interim Report (IR). Furthermore, the text explicitly states that the full results and related commentary will be released on March 6, 2013, indicating this document is the preliminary release. Therefore, it fits the definition of an Earnings Release (ER). FY 2012
2013-02-08 French
Guerbet - 2012 Revenue
Earnings Release Classification · 98% confidence The document is titled "PRESS RELEASE" and provides consolidated revenue figures for the full year 2012 compared to 2011, broken down by quarter and region. It discusses key product performance (Dotarem, Xenetix) and mentions future expectations for operating income and debt. Crucially, it states: "A complete presentation of results for fiscal 2012 with comments will be published on 6 March 2013." This indicates the document is an initial, high-level announcement of financial results, not the comprehensive report itself (like a 10-K or IR). This aligns perfectly with the definition of an Earnings Release (ER), which provides key highlights before the full report is released. FY 2012
2013-02-08 English
Guerbet - Nombre d'actions et de droits de vote au 31 Décembre 2012
Share Issue/Capital Change Classification · 95% confidence The document is titled "DECLARATION RELATIVE AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL DE LA SOCIETE" (Declaration relative to the number of shares and voting rights comprising the company's capital). It explicitly references French regulatory articles (Code de commerce, AMF general regulation) requiring monthly publication of the total number of voting rights and shares. The content is a table detailing the share count and voting rights as of December 31, 2012. This type of mandatory periodic disclosure regarding the capital structure and voting rights aligns most closely with a general regulatory filing or a specific disclosure related to capital structure changes, although none of the specific codes perfectly match a 'Monthly Capital Declaration'. Given the options, this is a mandatory regulatory disclosure that doesn't fit 10-K, ER, or IR. It is a specific disclosure about the capital structure, which is related to 'Share Issue/Capital Change' (SHA) or a general 'Regulatory Filing' (RNS). Since it is a formal, periodic declaration mandated by financial regulators (AMF) concerning the total voting rights and capital structure, it is best classified as a general Regulatory Filing (RNS) or potentially related to SHA, but RNS is the broader, safer category for mandatory, non-standard reports. However, since it is a formal declaration about the composition of the capital, it is a specific type of regulatory filing. Given the options, and noting that it is a formal declaration about the capital structure, it is a specific regulatory disclosure. Since there is no specific code for 'Monthly Voting Rights Declaration', RNS (Regulatory Filings) is the most appropriate fallback for a mandatory regulatory disclosure that isn't a primary financial report or management announcement.
2013-01-29 French
Admission de Guerbet au SRD Long-seulement
Share Issue/Capital Change Classification · 95% confidence The document is a "COMMUNIQUE DE PRESSE" (Press Release) dated December 20, 2012, announcing that Guerbet's stock will be admitted to the "SRD long-seulement" (a deferred settlement service allowing leverage) starting December 24, 2012, due to increased liquidity. This is a specific announcement regarding market access and trading mechanisms for the stock, not a core financial report (like 10-K or IR) or a standard regulatory filing like insider trading or dividend notice. Since it is a specific announcement concerning market operations and investor access, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially Capital/Financing Update (CAP) if the change in trading mechanism is viewed as a capital structure event. Given the context of market access and trading rules, RNS is the most appropriate general regulatory announcement category when a more specific one (like SHA or POS) doesn't apply directly to issuance or buybacks. However, since the announcement directly impacts how investors can trade the security (leveraged trading), it is a significant market/financing-related update. Comparing the options, RNS is the fallback, but this is a very specific market mechanism announcement. Since it is not a standard financial report, and it's not about dividends, M&A, or insider dealing, RNS serves as the best fit for a non-standard regulatory communication.
2012-12-20 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.